

# United States Patent and Trademark Office

m

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/015,220	10/26/2001	Michael W. Dae	RADNT-031A	6591	
33197 75	590 11/21/2003		EXAMINER		
STOUT, UXA, BUYAN & MULLINS LLP			HAYES, MICHAEL J		
4 VENTURE, SUITE 300 IRVINE, CA 92618			ART UNIT	PAPER NUMBER	
,			3763	//	

DATE MAILED: 11/21/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

			_
	Application N .	Applicant(s)	
	10/015,220	DAE ET AL.	
Office Action Summary	Examin r	Art Unit	
	Michael J Hayes	3763	_
The MAILING DATE of this communication ap Period for Reply	pears n the cover sheet with the o	rrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a rep - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut - Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).  Status	136(a). In no event, however, may a reply be tinoly within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	mely filed /s will be considered timely. If the mailing date of this communication. ID (35 U.S.C. § 133).	
1) Responsive to communication(s) filed on 21 A	<u>August 2003</u> .		
2a)⊠ This action is <b>FINAL</b> . 2b)☐ This	action is non-final.		
3) Since this application is in condition for allowards closed in accordance with the practice under			
Disposition of Claims			
4) Claim(s) 19-27 is/are pending in the application 4a) Of the above claim(s) 26 is/are withdrawn 5) Claim(s) is/are allowed. 6) Claim(s) 19-25 and 27 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	from consideration.		
Application Papers			
9) The specification is objected to by the Examina 10) The drawing(s) filed on 26 October 2001 is/are Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Epriority under 35 U.S.C. §§ 119 and 120	e: a)⊠ accepted or b)⊡ objected e drawing(s) be held in abeyance. Se ction is required if the drawing(s) is ob	e 37 CFR 1.85(a). ojected to. See 37 CFR 1.121(d).	
12) Acknowledgment is made of a claim for foreignal All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list 13) Acknowledgment is made of a claim for domes since a specific reference was included in the first 37 CFR 1.78.  a) The translation of the foreign language professional translation of the foreign language professional translation of the first sentence of the foreign language professional translation of the first sentence of the foreign language professional translation of the first sentence of the foreign language professional translation of the first sentence of	ats have been received.  Its have been received in Applicational documents have been received in Application (PCT Rule 17.2(a)).  It of the certified copies not receive tic priority under 35 U.S.C. § 119 (rest sentence of the specification of the covisional application has been received tic priority under 35 U.S.C. §§ 120	ion No  ed in this National Stage  ed.  e) (to a provisional application)  r in an Application Data Sheet.  ceived.  and/or 121 since a specific	
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)	

Application/Control Number: 10/015,220

Art Unit: 3763

#### **DETAILED ACTION**

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 19-25 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over DOBAK, III (US 2001/0041923), WARD (U. S. Patent No. 5,531,776) and WORTHEN (U. S. Patent No. 6,554,797). Dobak teaches the use of a heat exchange catheter inserted in the vena cava to induce hypothermia to 34°C to achieve indirect cooling to chosen organs while preferentially supplying blood to the heart and brain (0017). Dobak also teaches the use of warming blanket or thermoregulatory drugs to limit thermoregulatory defenses during induced hypothermia (0104, 0105). Dobak does not disclose the use of intra-aortic balloon pumping with patient body cooling or a patient temperature sensor and controller for heat exchanger control. Ward discloses the use of hypothermia with intra-aortic balloon pumping (col. 6, lines 44-55). It would have been obvious to one of ordinary skill in the art at the time of the invention to use the teachings of Ward in the invention of Dobak in order to improve outcome of victims of head trauma. See Ward 5:16-6:65. Worthen teaches a patient temperature sensor and controller for heat exchanger control (2:36-47). It would have been obvious to one of ordinary skill in the art at the time of the invention to use the sensor and controller as taught by Worthen in the method of Dobak and Ward in order to control the amount and rate that heat is removed from the patient. Art Unit: 3763

## Response to Arguments

Applicant argues that Ward does not teach using concurrent administration of hypothermia and intra-aortic balloon pumping. The examiner disagrees and refers Applicant to Ward col. 6, lines 44-55.

#### Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Hayes at (703) 305-5873. The examiner can usually be reached Monday -Thursday, 7:00-4:30, and on alternate Fridays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler, can be contacted at (703) 308-3552. The fax number for submitting official papers is (703) 872-9306.

mjh

17 November 2003

Michael // Hayer

PRIMARY EXAMINER